- Ortho's new VITROS® Anti-SARS-CoV-2 Total 2 Antibody assay and VITROS® Anti-SARS-CoV-2 IgG 2 Antibody assay receive CE Mark - Both tests can aid in identifying individuals with an adaptive immune ...

- Ortho's VITROS ® SARS-CoV-2 Antigen Test is the first high-volume COVID-19 antigen test to receive Authorization by Health Canada - With utility for mass-scale testing and same-day results for labs, ...

- Ortho's new VITROS ® Anti-SARS-CoV-2 IgG Quantitative Antibody test targets the S1 spike protein and is calibrated to the WHO International Standard for anti-SARS-CoV-2 IgG antibodies, which gives ...

Vaccination rates may be steadily climbing across the country, but companies hope COVID-19 testing won't slow down any time soon. In fact, manufacturers are now ramping up production of antigen and ...

Ortho Clinical Diagnostics, a global leader of in vitro diagnostics with a rich history of bringing critical tests for infectious diseases to market, today introduced and announced the U.S. Food and ...

- Ortho's new VITROS ® Anti-SARS-CoV-2 IgG Quantitative Test targets the S1 spike protein and is calibrated to the WHO International Standard for anti-SARS-CoV-2 IgG antibodies, which gives clinicians ...

- Ortho receives FDA Emergency Use Authorization for its second COVID-19 antibody test - Similar to Ortho's total COVID-19 antibody test, Ortho's IgG test demonstrated 100% specificity and can be used ...

Ortho Clinical Diagnostics, a global leader of in vitro diagnostics with a rich history of bringing critical tests for infectious diseases to market, today announced its second COVID-19 antibody ...

- Ortho's new VITROS ® Anti-SARS-CoV-2 Total 2 Antibody assay and VITROS ® Anti-SARS-CoV-2 IgG 2 Antibody assay receive CE Mark - Both tests can aid in identifying individuals with an adaptive immune ...

Ortho Clinical Diagnostics is hoping to pay down a large portion of its debts by riding a wave of COVID-19 and broader in vitro lab testing demands to a $1.5 billion IPO. The company is offering 70 ...